🌿 Omega-3 Fish Oil Triglyceride & Cardiovascular Evidence Simulator

Hypertriglyceridemia — The Starting Point

Fasting triglycerides climb when the liver makes more VLDL than the body clears.

• <150: Normal TG threshold (mg/dL, ATP III cutoff)
• ≥500: Very high TG (mg/dL, pancreatitis risk)
• ~25%: US adults w/ high TG (NHANES estimate)
• ~90%: Hepatic VLDL source (of plasma triglyceride)

What is hypertriglyceridemia

Fasting triglycerides above 150 mg/dL define hypertriglyceridemia.

Liver as triglyceride source

Liver packages fatty acids into VLDL triglyceride particles.

Severe cases exceed 500 mg/dL, risking acute pancreatitis.

Cardiovascular risk link

Very high triglycerides raise pancreatitis and cardiovascular risk.

EPA/DHA Supplementation Starts

Marine omega-3 fatty acids enter the bloodstream at a dose-dependent rate.

• 2–4: Effective EPA+DHA dose (g/day, clinical range)
• 4 g: Icosapent ethyl (EPA) (per day, REDUCE-IT dose)
• ~37 h: Plasma EPA half-life (approximate)
• 2–4: Onset of TG effect (weeks, initial response)

EPA and DHA sources

Marine fish oil supplies eicosapentaenoic and docosahexaenoic acids.

Prescription vs OTC omega-3

Prescription formulations deliver higher, purer EPA/DHA doses.

Doses below 2 g/day rarely lower triglycerides meaningfully.

Dose determines effect size

Larger daily dose produces greater triglyceride reduction.

Hepatic Triglyceride Synthesis Is Reduced

Omega-3 fatty acids reprogram liver gene expression away from fat storage.

• DGAT2: VLDL synthesis pathway (key hepatic enzyme)
• ↑ PPAR-α: Fatty acid oxidation (activated by EPA/DHA)
• ↓ SREBP-1c: Lipogenesis transcription (suppressed)
• ↓30%: Hepatic TG output (at high dose)

Suppressing lipogenesis

Omega-3 fatty acids downregulate SREBP-1c, cutting fat synthesis.

Boosting fatty acid oxidation

PPAR-alpha activation shifts fatty acids toward burning, not storage.

Reduced synthesis and increased oxidation work together.

Less substrate for VLDL

Fewer triglycerides assembled means less VLDL secreted.

Triglyceride Level Declines

Blood triglycerides fall over weeks, tracking dose and baseline severity.

• ~45%: Max TG reduction (severe hypertriglyceridemia)
• linear: Dose-response slope (0–4 g/day)
• minimal: HDL-C change (variable across trials)
• may rise: LDL-C change (with EPA+DHA mix)

Dose-response curve

Triglyceride reduction scales roughly linearly with omega-3 dose.

Severity affects magnitude

Higher baseline triglycerides show larger absolute drops.

Severe hypertriglyceridemia can fall by up to 45 percent.

Timeline to full effect

Maximal triglyceride lowering typically takes four to eight weeks.

Cardiovascular Evidence Assessment

Triglyceride-lowering is consistent, but cardiovascular event evidence is mixed.

• -25%: REDUCE-IT (EPA-only) (MACE, icosapent ethyl)
• no benefit: STRENGTH (EPA+DHA) (trial halted)
• -19%: JELIS (Japan) (events, EPA add-on)
• no benefit: VITAL (low-dose) (1 g/day general pop)

Triglyceride evidence is strong

Multiple trials confirm consistent, dose-dependent triglyceride lowering.

Cardiovascular evidence is mixed

Pure EPA trials show benefit; EPA+DHA trials often don't.

REDUCE-IT succeeded with EPA-only; STRENGTH with EPA+DHA failed.

Why results diverge

Formulation, dose, and comparator oil may explain differences.

Key cardiovascular outcome trials